2-[(Tert-butoxycarbonyl)amino]-3-(3,4-difluorophenyl)propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(Tert-butoxycarbonyl)amino]-3-(3,4-difluorophenyl)propanoic acid
• 英文别名: 3-(3,4-difluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• 化学式: C₁₄H₁₇F₂NO₄
• 分子量: 301.29
• InChiKey: CYAOPVHXASZUDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Substituted hydantoins
  申请人：Goodnow, Alan Robert

  公开号：US20060063814A1

  公开（公告）日：2006-03-23

  The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

  本发明涉及以下公式的化合物，这些化合物在治疗以MEK高活性为特征的疾病方面具有用途。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病方面具有用途。
• [EN] ENZYME INHIBITORS<br/>[FR] INHIBITEURS D'ENZYMES
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2021032933A1

  公开（公告）日：2021-02-25

  The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.

  本发明提供了如下式(I)的化合物：化合物组合物；在治疗中使用这些化合物；以及使用这些化合物治疗患者的方法；其中A、Y、n、R1、R2A、R2B、R3和*1如本文所定义。
• [EN] BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] DÉRIVÉS DE BENZYLAMINE EN TANT QU'INHIBITEURS DE KALLIKRÉINE DU PLASMA
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2013005045A1

  公开（公告）日：2013-01-10

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.

  本发明提供了如下式（I）的化合物：包含这些化合物的组合物；在治疗中使用这些化合物（例如在涉及血浆激肽酶活性的疾病或症状的治疗或预防中）；以及使用这些化合物治疗患者的方法；其中R1至R9如本文中所定义。
• [EN] INHIBITORS OF DIPEPTIDYL PEPTIDASE IV<br/>[FR] INHIBITEURS DE LA DIPEPTIDYL-PEPTIDASE IV
  申请人：ASTRAZENECA AB

  公开号：WO2005040095A1

  公开（公告）日：2005-05-06

  The invention relates to compounds of the formula (I) or pharmaceutically-acceptable salts thereof wherein Ar, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 have any of the meanings defined in the description, which possess dipeptidyl peptidase IV (DPP-IV) inhibitory activity and accordingly have value in the treatment of disease states associated with DPP-IV activity, such as diabetes mellitus. Processes for the preparation of said compounds, intermediates in said processes, pharmaceutical compositions containing said compounds or salts, and the use of said compounds or salts are also described.

  该发明涉及式（I）的化合物或其药学上可接受的盐，其中Ar，R1，R2，R3，R4，R5，R6，R7和R8具有描述中定义的任何含义，这些化合物具有二肽基肽酶IV（DPP-IV）抑制活性，因此在治疗与DPP-IV活性相关的疾病状态，如糖尿病等方面具有价值。还描述了制备该化合物的方法，该方法中间体，含有该化合物或其盐的药物组合物以及使用该化合物或其盐的用途。
• DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
  申请人：Mitchell Ian S.

  公开号：US20120329808A1

  公开（公告）日：2012-12-27

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供包括已解析的对映体、顺反异构体、溶剂化物及其药学上可接受的盐的化合物，其化学式为：同时，本发明还提供使用该化合物作为AKT蛋白激酶抑制剂及用于治疗高增殖性疾病如癌症的方法。